Answers are grounded in this paper and cite their sources.
Antibody therapies are a crucial component of modern lymphoid malignancy treatment and an exciting area of active research. We performed a review of modern antibody therapies used in the treatment of lymphoid malignancies, with an emphasis on landmark studies and current directions. We describe the indications for rituximab, obinutuzumab, ADCs, and bispecific antibody therapies. Finally, we summarize early data from ongoing trials on emerging novel therapy combination regimens and discuss the role of machine learning in future therapy development.
No takes yet. Share an insight, caveat, or question.
Naman et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: